{"id":"ndc-vaccination","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, or swelling at the injection site"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL2107962","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This is achieved through the introduction of a piece of genetic material from the virus, which triggers the body's immune system to produce antibodies and immune cells that can recognize and fight the virus. The vaccine works by providing the body with a blueprint for the virus's spike protein, allowing the immune system to mount a targeted response.","oneSentence":"The nDC vaccination induces an immune response against the SARS-CoV-2 virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:22:33.080Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of COVID-19 disease caused by SARS-CoV-2 virus"}]},"trialDetails":[{"nctId":"NCT02993315","phase":"PHASE3","title":"Melanoma Patients Immunized with Natural DenDritic Cells","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2016-10","conditions":"Melanoma (Skin)","enrollment":148},{"nctId":"NCT05327426","phase":"PHASE1","title":"Intradermal Fractional Dose IPV (fIPV) in Combination With dmLT","status":"UNKNOWN","sponsor":"University of Vermont","startDate":"2022-04-01","conditions":"Poliomyelitis","enrollment":19},{"nctId":"NCT02987374","phase":"PHASE4","title":"Pilot Study in Young Adults to Examine the Kinetics of Changes in the B-cell Repertoire Following TIV Immunization","status":"COMPLETED","sponsor":"Stanford University","startDate":"2012-05","conditions":"Influenza","enrollment":10},{"nctId":"NCT00437671","phase":"PHASE4","title":"Tetanus Immunization in Subjects With No Immunization History or With Tetanus Antibody Levels Below Protective Levels","status":"TERMINATED","sponsor":"Grifols Therapeutics LLC","startDate":"2007-03","conditions":"Tetanus","enrollment":6},{"nctId":"NCT00342628","phase":"PHASE2","title":"Safety, Immunogenicity and Compatibility With DTP of a Typhoid Fever Vaccine in Infants","status":"COMPLETED","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"2006-07","conditions":"Typhoid Fever","enrollment":301}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"nDC vaccination","genericName":"nDC vaccination","companyName":"Radboud University Medical Center","companyId":"radboud-university-medical-center","modality":"Biologic","firstApprovalDate":"","aiSummary":"The nDC vaccination is a vaccine component that induces an immune response, as per its classification as a biological vaccine. It has been studied in clinical trials for various conditions, including melanoma, typhoid fever, tetanus, influenza, and poliomyelitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}